Karolina Kaźmierczak-Siedlecka

Dr. Karolina Kaźmierczak-Siedlecka

Department of Surgical Oncology, Medical University of Gdansk
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in Gut Microbes
Verified
Journal Article
Open access
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
ADAgnieszka Daca
Agnieszka Daca
MFMateusz Fic
Mateusz Fic
TWThierry van de Wetering
Thierry van de Wetering
MFMarcin Folwarski
Marcin Folwarski
WMWojciech Makarewicz
Wojciech Makarewicz
The link between gut microbiota and the development of colorectal cancer has been investigated. An imbalance in the gut microbiota promotes the progress of colorectal carcinogenesis via multiple mechanisms, including inflammation, activation of carcinogens, and tumorigenic pathways as well as damaging host DNA. Several therapeutic methods are available with which to alter the composition and the activity of gut microbiota, such as administration of prebiotics, probiotics, and synbiotics; these can confer various benefits for colorectal cancer patients. Nowadays, fecal microbiota transplantation is the most modern way of modulating the gut microbiota. Even though data regarding fecal microbiota transplantation in colorectal cancer patients are still rather limited, it has been approved as a clinical method of treatment-recurrent Clostridium difficile infection, which may also occur in these patients. The major benefits of fecal microbiota transplantation include modulation of immunotherapy efficacy, amelioration of bile acid metabolism, and restoration of intestinal microbial diversity. Nonetheless, more studies are needed to assess the long-term effects of fecal microbiota transplantation. In this review, the impact of gut microbiota on the efficiency of anti-cancer therapy and colorectal cancer patients’ overall survival is also discussed.

18 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
KJKatarzyna Jagłowska
Katarzyna Jagłowska
MFMarcin Folwarski
Marcin Folwarski
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
Karolina Skonieczna-ŻydeckaKarolina Skonieczna-Żydecka
Karolina Skonieczna-Żydecka
JKJan Jacek Kaczor
Jan Jacek Kaczor
Excessive training may limit physiological muscle adaptation through chronic oxidative stress and inflammation. Improper diet and overtraining may also disrupt intestinal homeostasis and in consequence enhance inflammation. Altogether, these factors may lead to an imbalance in the gut ecosystem, causing dysregulation of the immune system. Therefore, it seems to be important to optimize the intestinal microbiota composition, which is able to modulate the immune system and reduce oxidative stress. Moreover, the optimal intestinal microbiota composition may have an impact on muscle protein synthesis and mitochondrial biogenesis and function, as well as muscle glycogen storage. Aproperly balanced microbiome may also reduce inflammatory markers and reactive oxygen species production, which may further attenuate macromolecules damage. Consequently, supplementation with probiotics may have some beneficial effect on aerobic and anaerobic performance. The phenomenon of gut-muscle axis should be continuously explored to function maintenance, not only in athletes.

15 February 2022 in Gut Microbes
Verified
Journal Article
Open access
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
KSKarolina Skonieczna-Żydecka
Karolina Skonieczna-Żydecka
THTheodore Hupp
Theodore Hupp
RDRenata Duchnowska
Renata Duchnowska
Natalia Marek- TrzonkowskaNatalia Marek- Trzonkowska
Natalia Marek- Trzonkowska
KPKarol Połom
Karol Połom
Gut microbiota and its association with cancer development/treatment has been intensively studied during the past several years. Currently, there is a growing interest toward next-generation probiotics (NGPs) as therapeutic agents that alter gut microbiota and impact on cancer development. In the present review we focus on three emerging NGPs, namely Faecalibacterium prausnitzii, Akkermansia muciniphila, and Bacteroides fragilis as their presence in the digestive tract can have an impact on cancer incidence. These NGPs enhance gastrointestinal immunity, maintain intestinal barrier integrity, produce beneficial metabolites, act against pathogens, improve immunotherapy efficacy, and reduce complications associated with chemotherapy and radiotherapy. Notably, the use of NGPs in cancer patients does not have a long history and, although their safety remains relatively undefined, recently published data has shown that they are non-toxigenic. Notwithstanding, A. muciniphila may promote colitis whereas enterotoxigenic B. fragilis stimulates chronic inflammation and participates in colorectal carcinogenesis. Nevertheless, the majority of B. fragilis strains provide a beneficial effect to the host, are non-toxigenic and considered as the best current NGP candidate. Overall, emerging studies indicate a beneficial role of these NGPs in the prevention of carcinogenesis and open new promising therapeutic options for cancer patients.

29 May 2020 in Current Microbiology
Verified
Journal Article
Open access
PDF file
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
JRJakub Ruszkowski
Jakub Ruszkowski
MFMateusz Fic
Mateusz Fic
MFMarcin Folwarski
Marcin Folwarski
WMWojciech Makarewicz
Wojciech Makarewicz
The yeast Saccharomyces boulardii CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. adhesion to and elimination of enteropathogenic microorganisms and their toxins; extracellular cleavage of pathogens’ virulent factors; trophic and anti-inflammatory effects on the intestinal mucosa. The efficacy of S. boulardii administration was tested in variety of human diseases. We discussed the results of S. boulardii CNCM I-745 use in the treatment or prevention of Helicobacter pylori infections, diarrhoea (Clostridium difficile infections, antibiotic-associated diarrhoea, and traveller’s diarrhoea), inflammatory bowel diseases, irritable bowel syndrome, candidiasis, dyslipidemia, and small intestine bacterial overgrowth in patients with multiple sclerosis. In case of limited number of studies regarding this strain, we also presented studies demonstrating properties and efficacy of other strains of S. boulardii. Administration of S. boulardii CNCMI I-745 during antibiotic therapy has certain advantage over bacterial probiotics, because—due to its fungal natural properties—it is intrinsically resistant to the antibiotics and cannot promote the spread of antimicrobial resistance. Even though cases of fungemia following S. boulardii CNCM I-745 administration were reported, it should be treated as a widely available and safe probiotic strain.

26 October 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
LMLuigi Marano
Luigi Marano
EMElvira Merola
Elvira Merola
FRFranco Roviello
Franco Roviello
KPKarol Połom
Karol Połom
Accumulating evidence suggests that selected microbiota-derived metabolites play a significant role in both tumor prevention and supportive treatment of cancer. Short-chain fatty acids (SCFAs), i.e., mainly acetate, proprionate, and butyrate, are one of them. Nowadays, it is known that butyrate is a key microbial metabolite. Therefore, in the current review, we focused on butyrate and sodium butyrate (NaB) in the context of colorectal cancer. Notably, butyrate is characterized by a wide range of beneficial properties/activities. Among others, it influences the function of the immune system, maintains intestinal barrier integrity, positively affects the efficiency of anti-cancer treatment, and may reduce the risk of mucositis induced by chemotherapy. Taking into consideration these facts, we analyzed NaB (which is a salt of butyric acid) and its impact on gut microbiota as well as anti-tumor activity by describing molecular mechanisms. Overall, NaB is available as, for instance, food with special medical purposes (depending on the country’s regulation), and its administration seems to be a promising option for colorectal cancer patients.

31 July 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Karolina Kaźmierczak-SiedleckaKarolina Kaźmierczak-Siedlecka
Karolina Kaźmierczak-Siedlecka
giandomenico roviellogiandomenico roviello
giandomenico roviello
MCMartina Catalano
Martina Catalano
KPKarol Polom
Karol Polom
Accumulating evidence has revealed the critical roles of commensal microbes in cancer progression and recently several investigators have evaluated the therapeutic effectiveness of targeting the microbiota. This gut microbiota-related approach is especially attractive in the treatment of gastrointestinal cancers. Probiotics supplementation is a microbiota-targeted strategy that appears to improve treatment efficacy; Lactobacillus spp. and Bifidobacterium spp. are among the most commonly used probiotic agents. These bacteria seem to exert immunomodulatory effects, impacting on the immune system both locally and systemically. The gut microbiota are able to affect the efficiency of immunotherapy, mainly acting as inhibitors at immune checkpoints. The effects of immunotherapy may be modulated using traditional probiotic strains and/or next generation probiotics, such as Akkermansia municiphila. It is possible that probiotics might enhance the efficiency of immunotherapy based on PD-1/PD-L1 and CTLA-4 but more data are needed to confirm this speculation. Indeed, although there is experimental evidence for the efficacy of several strains, the health-promoting effects of numerous probiotics have not been demonstrated in human patients and furthermore the potential risks of these products, particularly in oncologic patients, are rarely mentioned.